Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Posterior Fossa Lesion Load and Pathological Laughing and Crying in Multiple Sclerosis.

Luhoway JA, Sharma M, Menon S, Rosehart H, Morrow SA.

Int J MS Care. 2019 May-Jun;21(3):135-142. doi: 10.7224/1537-2073.2018-016.

2.

Severe sequential visual loss in MS co-diagnosis of Leber's hereditary optic neuropathy.

Riccio PM, Fraser JA, Lee DH, Morrow SA.

Can J Ophthalmol. 2019 Apr;54(2):e69-e70. doi: 10.1016/j.jcjo.2018.06.020. Epub 2018 Aug 30. No abstract available.

PMID:
30975365
3.

Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.

Silveira CRA, MacKinley J, Coleman K, Li Z, Finger E, Bartha R, Morrow SA, Wells J, Borrie M, Tirona RG, Rupar CA, Zou G, Hegele RA, Mahuran D, MacDonald P, Jenkins ME, Jog M, Pasternak SH.

BMC Neurol. 2019 Feb 9;19(1):20. doi: 10.1186/s12883-019-1252-3.

4.

Clinical Determinants of Fitness to Drive in Persons With Multiple Sclerosis: Systematic Review.

Krasniuk S, Classen S, Morrow SA, Tippett M, Knott M, Akinwuntan A.

Arch Phys Med Rehabil. 2019 Jan 26. pii: S0003-9993(19)30013-9. doi: 10.1016/j.apmr.2018.12.029. [Epub ahead of print] Review.

PMID:
30690007
5.

Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches.

Grand'Maison F, Yeung M, Morrow SA, Lee L, Emond F, Ward BJ, Laneuville P, Schecter R.

Neural Regen Res. 2018 Nov;13(11):1871-1874. doi: 10.4103/1673-5374.239432. Review.

6.

Depressive Symptoms Are Associated With More Negative Functional Outcomes Than Anxiety Symptoms in Persons With Multiple Sclerosis.

Gill S, Santo J, Blair M, Morrow SA.

J Neuropsychiatry Clin Neurosci. 2019 Winter;31(1):37-42. doi: 10.1176/appi.neuropsych.18010011. Epub 2018 Sep 6.

PMID:
30187820
7.

Short Report: Prevalence of Cognitive Impairment in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis.

DiGiuseppe G, Blair M, Morrow SA.

Int J MS Care. 2018 Jul-Aug;20(4):153-157. doi: 10.7224/1537-2073.2017-029.

8.

Pearls & Oy-sters: An unusual neuropsychiatric manifestation of systemic lupus erythematosus.

Kim DD, Ho C, King R, Morrow SA.

Neurology. 2018 May 22;90(21):e1929-e1932. doi: 10.1212/WNL.0000000000005555. No abstract available.

PMID:
29784725
9.

Toward a Shared-Care Model of Relapsing-Remitting Multiple Sclerosis: Role of the Primary Care Practitioner.

Oh J, Gagné-Brosseau MS, Guenette M, Larochelle C, Lemieux F, Menon S, Morrow SA, Poliquin-Lasnier L, Roy-Hewitson C, Rush C, Trudelle AM, Giacomini PS.

Can J Neurol Sci. 2018 May;45(3):304-312. doi: 10.1017/cjn.2018.7.

PMID:
29756588
10.

Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment.

Grand'Maison F, Yeung M, Morrow SA, Lee L, Emond F, Ward BJ, Laneuville P, Schecter R.

Curr Med Res Opin. 2018 Aug;34(8):1419-1430. doi: 10.1080/03007995.2018.1458023. Epub 2018 Apr 18.

PMID:
29583054
11.

Effect of Treating Acute Optic Neuritis With Bioequivalent Oral vs Intravenous Corticosteroids: A Randomized Clinical Trial.

Morrow SA, Fraser JA, Day C, Bowman D, Rosehart H, Kremenchutzky M, Nicolle M.

JAMA Neurol. 2018 Jun 1;75(6):690-696. doi: 10.1001/jamaneurol.2018.0024.

12.

Anti-cholinergic medications for bladder dysfunction worsen cognition in persons with multiple sclerosis.

Morrow SA, Rosehart H, Sener A, Welk B.

J Neurol Sci. 2018 Feb 15;385:39-44. doi: 10.1016/j.jns.2017.11.028. Epub 2017 Nov 22.

PMID:
29406911
13.

Anxiety is more important than depression in MS - Yes.

Morrow SA.

Mult Scler. 2018 Apr;24(4):440-441. doi: 10.1177/1352458517751652. Epub 2018 Jan 30. No abstract available.

PMID:
29381115
14.

Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group.

Members of the MS in the 21st Century Steering Group:, Rieckmann P, Centonze D, Elovaara I, Giovannoni G, Havrdová E, Kesselring J, Kobelt G, Langdon D, Morrow SA, Oreja-Guevara C, Schippling S, Thalheim C, Thompson H, Vermersch P, Aston K, Bauer B, Demory C, Giambastiani MP, Hlavacova J, Nouvet-Gire J, Pepper G, Pontaga M, Rogan E, Rogalski C, van Galen P, Ben-Amor AF.

Mult Scler Relat Disord. 2018 Jan;19:153-160. doi: 10.1016/j.msard.2017.11.013. Epub 2017 Nov 21.

15.

On-road assessment of fitness-to-drive in persons with MS with cognitive impairment: A prospective study.

Morrow SA, Classen S, Monahan M, Danter T, Taylor R, Krasniuk S, Rosehart H, He W.

Mult Scler. 2018 Oct;24(11):1499-1506. doi: 10.1177/1352458517723991. Epub 2017 Aug 7.

PMID:
28782411
16.

Visual Correlates of Fitness to Drive in Adults With Multiple Sclerosis.

Classen S, Krasniuk S, Morrow SA, Alvarez L, Monahan M, Danter T, Rosehart H.

OTJR (Thorofare N J). 2018 Jan;38(1):15-27. doi: 10.1177/1539449217718841. Epub 2017 Aug 2.

PMID:
28766462
17.

Understanding leisure-time physical activity: Voices of people with MS who have moderate-to-severe disability and their family caregivers.

Fakolade A, Lamarre J, Latimer-Cheung A, Parsons T, Morrow SA, Finlayson M.

Health Expect. 2018 Feb;21(1):181-191. doi: 10.1111/hex.12600. Epub 2017 Jul 19.

18.

Self-reported maximum walking distance in persons with MS may affect the EDSS.

Berger W, Payne MWC, Morrow SA.

J Neurol Sci. 2017 Aug 15;379:77-80. doi: 10.1016/j.jns.2017.05.035. Epub 2017 May 17.

PMID:
28716284
19.

The risk of dementia with the use of 5 alpha reductase inhibitors.

Welk B, McArthur E, Ordon M, Morrow SA, Hayward J, Dixon S.

J Neurol Sci. 2017 Aug 15;379:109-111. doi: 10.1016/j.jns.2017.05.064. Epub 2017 May 31.

PMID:
28716218
20.

Canadian Normative Data for Minimal Assessment of Cognitive Function in Multiple Sclerosis.

Walker LAS, Marino D, Berard JA, Feinstein A, Morrow SA, Cousineau D.

Can J Neurol Sci. 2017 Sep;44(5):547-555. doi: 10.1017/cjn.2017.199. Epub 2017 Jul 7.

PMID:
28683843
21.

Normal appearing white matter permeability: a marker of inflammation and information processing speed deficit among relapsing remitting multiple sclerosis patients.

Eftekhari E, Hojjat SP, Vitorino R, Carroll TJ, Cantrell CG, Lee L, Taylor MW, Morrow SA, Benhabib H, Aviv RI, Kassner A.

Neuroradiology. 2017 Aug;59(8):771-780. doi: 10.1007/s00234-017-1862-7. Epub 2017 Jun 16.

PMID:
28623483
22.

Driving Errors That Predict On-Road Outcomes in Adults With Multiple Sclerosis.

Krasniuk S, Classen S, Morrow SA, Monahan M, Danter T, Rosehart H, He W.

OTJR (Thorofare N J). 2017 May 1:1539449217708554. doi: 10.1177/1539449217708554. [Epub ahead of print]

PMID:
28539098
23.

The effect of Fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS.

Morrow SA, Rosehart H, Johnson AM.

Mult Scler Relat Disord. 2017 Jan;11:4-9. doi: 10.1016/j.msard.2016.10.011. Epub 2016 Nov 4.

PMID:
28104253
24.

Developing easy to perform routine MRI measurements as potential surrogates for cognitive impairment in MS.

Morrow SA, Menon S, Rosehart H, Sharma M.

Clin Neurol Neurosurg. 2017 Feb;153:73-78. doi: 10.1016/j.clineuro.2016.12.015. Epub 2016 Dec 29.

PMID:
28061362
25.

Comparing depression screening tools in persons with multiple sclerosis (MS).

Hanna J, Santo JB, Blair M, Smolewska K, Warriner E, Morrow SA.

Rehabil Psychol. 2017 Feb;62(1):20-24. doi: 10.1037/rep0000115. Epub 2016 Dec 5.

PMID:
27918176
26.

Development and Validity of Western University's On-Road Assessment.

Classen S, Krasniuk S, Alvarez L, Monahan M, Morrow SA, Danter T.

OTJR (Thorofare N J). 2017 Jan;37(1):14-29. doi: 10.1177/1539449216672859. Epub 2016 Oct 15.

PMID:
27744272
27.

Association Between Gadolinium Contrast Exposure and the Risk of Parkinsonism.

Welk B, McArthur E, Morrow SA, MacDonald P, Hayward J, Leung A, Lum A.

JAMA. 2016 Jul 5;316(1):96-8. doi: 10.1001/jama.2016.8096. No abstract available.

PMID:
27380348
28.

Levodopa impairs probabilistic reversal learning in healthy young adults.

Vo A, Seergobin KN, Morrow SA, MacDonald PA.

Psychopharmacology (Berl). 2016 Jul;233(14):2753-63. doi: 10.1007/s00213-016-4322-x. Epub 2016 May 30.

PMID:
27241710
29.

Everything Old is New Again.

Florendo-Cumbermack A, Selchen D, Morrow SA, Sharma M, Steven D, Ang LC, Casserly C, Burneo J, Kremenchutzky M, Hammond R.

Can J Neurol Sci. 2016 Jan;43(1):213-8. doi: 10.1017/cjn.2015.309. No abstract available.

PMID:
27182570
30.

The mediating role of processing speed in the relationship between depressive symptoms and cognitive function in multiple sclerosis.

Blair M, Gill S, Gutmanis I, Smolewska K, Warriner E, Morrow SA.

J Clin Exp Neuropsychol. 2016 Sep;38(7):782-94. doi: 10.1080/13803395.2016.1164124. Epub 2016 May 4.

PMID:
27144616
31.

Perfusion reduction in the absence of structural differences in cognitively impaired versus unimpaired RRMS patients.

Hojjat SP, Cantrell CG, Carroll TJ, Vitorino R, Feinstein A, Zhang L, Symons SP, Morrow SA, Lee L, O'Connor P, Aviv RI.

Mult Scler. 2016 Nov;22(13):1685-1694. Epub 2016 Feb 4.

32.

Episodic Mood Changes Preceding an Exacerbation of Multiple Sclerosis.

Sharma P, Morrow SA, Owen RJ.

Prim Care Companion CNS Disord. 2015 Oct 29;17(5). doi: 10.4088/PCC.15br01815. eCollection 2015.

33.

The association of pathological laughing and crying and cognitive impairment in multiple sclerosis.

Hanna J, Feinstein A, Morrow SA.

J Neurol Sci. 2016 Feb 15;361:200-3. doi: 10.1016/j.jns.2016.01.002. Epub 2016 Jan 5.

PMID:
26810543
34.

Regional reduction in cortical blood flow among cognitively impaired adults with relapsing-remitting multiple sclerosis patients.

Hojjat SP, Cantrell CG, Vitorino R, Feinstein A, Shirzadi Z, MacIntosh BJ, Crane DE, Zhang L, Morrow SA, Lee L, O'Connor P, Carroll TJ, Aviv RI.

Mult Scler. 2016 Oct;22(11):1421-1428. Epub 2016 Jan 11.

35.

Anxiety and Depressive Symptoms Are Associated With Worse Performance on Objective Cognitive Tests in MS.

Morrow SA, Rosehart H, Pantazopoulos K.

J Neuropsychiatry Clin Neurosci. 2016 Spring;28(2):118-23. doi: 10.1176/appi.neuropsych.15070167. Epub 2015 Nov 16.

PMID:
26569152
36.

Plasma Exchange in a Patient with Tumefactive, Corticosteroid-Resistant Multiple Sclerosis.

Ikeda KM, Lee DH, Fraser JA, Mirsattari S, Morrow SA.

Int J MS Care. 2015 Sep-Oct;17(5):231-5. doi: 10.7224/1537-2073.2014-078.

37.

Depression and hypomania symptoms are associated with high dose corticosteroids treatment for MS relapses.

Morrow SA, Barr J, Rosehart H, Ulch S.

J Affect Disord. 2015 Nov 15;187:142-6. doi: 10.1016/j.jad.2015.08.040. Epub 2015 Aug 21.

PMID:
26334182
38.

Effects of single dose mixed amphetamine salts--extended release on processing speed in multiple sclerosis: a double blind placebo controlled study.

Morrow SA, Rosehart H.

Psychopharmacology (Berl). 2015 Dec;232(23):4253-9. doi: 10.1007/s00213-015-4051-6. Epub 2015 Aug 21.

PMID:
26289355
39.

Corrigendum to "Cardiovascular autonomic dysfunction in multiple sclerosis: A meta-analysis" [Mult. Scler. Relat. Disord. 4 (2015) 104-111].

Racosta JM, Sposato LA, Morrow SA, Cipriano L, Kimpinski K, Kremenchutzky M.

Mult Scler Relat Disord. 2015 Jul;4(4):385. doi: 10.1016/j.msard.2015.05.002. Epub 2015 May 18. No abstract available.

PMID:
26195062
40.

Posterior Reversible Encephalopathy Syndrome due to High Dose Corticosteroids for an MS Relapse.

Morrow SA, Rana R, Lee D, Paul T, Mahon JL.

Case Rep Neurol Med. 2015;2015:325657. doi: 10.1155/2015/325657. Epub 2015 May 26.

41.

Autonomic dysfunction in multiple sclerosis.

Racosta JM, Kimpinski K, Morrow SA, Kremenchutzky M.

Auton Neurosci. 2015 Dec;193:1-6. doi: 10.1016/j.autneu.2015.06.001. Epub 2015 Jun 7. Review.

PMID:
26070809
42.

Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group.

Rieckmann P, Boyko A, Centonze D, Elovaara I, Giovannoni G, Havrdová E, Hommes O, Kesselring J, Kobelt G, Langdon D, LeLorier J, Morrow SA, Oreja-Guevara C, Schippling S, Thalheim C, Thompson H, Vermersch P.

Mult Scler Relat Disord. 2015 May;4(3):202-18. doi: 10.1016/j.msard.2015.02.005. Epub 2015 Mar 2. Review.

43.

Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring.

Traboulsee A, Létourneau-Guillon L, Freedman MS, O'Connor PW, Bharatha A, Chakraborty S, Girard JM, Giuliani F, Lysack JT, Marriott JJ, Metz LM, Morrow SA, Oh J, Sharma M, Vandorpe RA, Vertinsky TA, Wadhwa VS, von Riedemann S, Li DK.

Can J Neurol Sci. 2015 May;42(3):159-67. doi: 10.1017/cjn.2015.24. Epub 2015 Apr 21.

44.

Predictors of chronic cerebrospinal venous insufficiency procedure use among older people with multiple sclerosis: a national case-control study.

Ploughman M, Manning OJ, Beaulieu S, Harris C, Hogan SH, Mayo N, Fisk JD, Sadovnick AD, O'Connor P, Morrow SA, Metz LM, Smyth P, Allderdice PW, Scott S, Marrie RA, Stefanelli M, Godwin M.

BMC Health Serv Res. 2015 Apr 16;15:161. doi: 10.1186/s12913-015-0835-y.

45.

Diagnosis and quantification of cognitive fatigue in multiple sclerosis.

Morrow SA, Rosehart H, Johnson AM.

Cogn Behav Neurol. 2015 Mar;28(1):27-32. doi: 10.1097/WNN.0000000000000050.

PMID:
25812128
46.

Cardiovascular autonomic dysfunction in multiple sclerosis: a meta-analysis.

Racosta JM, Sposato LA, Morrow SA, Cipriano L, Kimpinski K, Kremenchutzky M.

Mult Scler Relat Disord. 2015 Mar;4(2):104-11. doi: 10.1016/j.msard.2015.02.002. Epub 2015 Feb 23. Review. Erratum in: Mult Scler Relat Disord. 2015 Jul;4(4):385. Kimpiski, Kurt [Corrected to Kimpinski, Kurt].

PMID:
25787186
47.

Cognitive impairment in multiple sclerosis: clinical, radiologic and pathologic insights.

DeLuca GC, Yates RL, Beale H, Morrow SA.

Brain Pathol. 2015 Jan;25(1):79-98. doi: 10.1111/bpa.12220. Review.

PMID:
25521179
48.

Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect.

Schoedel KA, Morrow SA, Sellers EM.

Neuropsychiatr Dis Treat. 2014 Jun 26;10:1161-74. doi: 10.2147/NDT.S30713. eCollection 2014. Review.

49.

The Canadian survey of health, lifestyle and ageing with multiple sclerosis: methodology and initial results.

Ploughman M, Beaulieu S, Harris C, Hogan S, Manning OJ, Alderdice PW, Fisk JD, Sadovnick AD, O'Connor P, Morrow SA, Metz LM, Smyth P, Mayo N, Marrie RA, Knox KB, Stefanelli M, Godwin M.

BMJ Open. 2014 Jul 10;4(7):e005718. doi: 10.1136/bmjopen-2014-005718. Erratum in: BMJ Open. 2015;5(3):e005718.

50.

The conceptualization and development of a patient-reported neurogenic bladder symptom score.

Welk B, Morrow SA, Madarasz W, Potter P, Sequeira K.

Res Rep Urol. 2013 Oct 10;5:129-37. doi: 10.2147/RRU.S51020. eCollection 2013.

Supplemental Content

Loading ...
Support Center